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Background: Drooling saliva is a common problem in children with neurodevelopmental disorders. The negative
consequences of drooling include skin breakdown, dehydration, and damage to clothing and equipment. Children
and families often suffer social embarrassment due to drooling. There is no evidence about the relative
effectiveness, side effect profiles or patient acceptability of the two medications most commonly used to reduce
drooling - glycopyrronium and hyoscine. Consequently, there is no consensus or guideline to aid clinical decisions
about which drug to use, and at what dose.
Methods/design: A multi-centre, randomised trial of treatment with glycopyrronium or hyoscine in children with
problematic drooling and non-progressive neurodisability. Ninety children aged between 3 and 15 years who have
never received medication for drooling will be stratified by severity of drooling and care centre. Randomisation to
receive treatment with glycopyrronium or hyoscine will be computer generated from the trial randomisation
website. Dose adjustment and side effect monitoring will occur via telephone consultation. Medication arm will be
known to participants and clinicians but not the Trial Outcome Assessor.
The primary outcome measure is the Drooling Impact Scale score at four weeks, at which time all children will be
on the maximum tolerated dose of their medication. Secondary outcome measures include change in Drooling
Impact Scale score between baseline, 4, 12 and 52 weeks, change in Drooling Severity and Frequency Scale score
and difference between groups in the Treatment Satisfaction Questionnaire for Medication score. A structured
interview with children and young people of sufficient age, cognitive and communication ability will explore their
perceptions of drooling and the effectiveness and acceptability of the medications.
Discussion: The primary objective of the study is to identify whether glycopyrronium or hyoscine is more effective
in treating drooling in children with non-progressive neurodisability. The study will also determine which
medications at what doses are most acceptable and have fewest side effects. This information will be used to
develop evidence based guidance to inform the medical treatment of drooling.
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Study rationale
Drooling saliva, due to oro-motor impairment, is a com-
mon problem in children with neurodevelopmental disor-
ders. The negative consequences of drooling for children
and their relatives include skin breakdown of the child’s
chin, dehydration, and damage to clothing and equipment
such as electronic communication aids; furthermore, chil-
dren, their siblings and parents often suffer social embar-
rassment due to the physical appearance of drooling and
salivary spray when talking and eating [1]. Parents may have
to remind children to swallow pooled saliva. Bibs, or wrist-
bands are used to soak up saliva and clothing changes are
frequently required, resulting in extra washing loads [1,2].
There is no evidence about the relative effectiveness of the
medications most commonly used to reduce drooling.
There are only limited data about the medications’ side ef-
fects and how acceptable they are to children and parents;
this lack of information makes it difficult for children, par-
ents and doctors to make informed decisions about which
drug to use, and at what dose [1].
Around 35% of children with cerebral palsy have prob-
lematic drooling, equating to around 10,500 children in
the UK [3-5]. Children with cerebral palsy with Gross
Motor Classification System (GMFCS) levels IV and V
are five and thirteen times respectively more likely to ex-
perience problematic drooling than children classified as
GMFCS level I [3], and Parkes, personal communication.
A survey we conducted showed that UK paediatricians
see on average one treatment naive child per month with
problematic drooling [6].
Current treatment and its limitations
Medication is the first intervention used to treat drooling
by most UK clinicians. Both glycopyrronium and hyoscine
work by reducing cholinergic stimulation of salivary glands,
and the volume of saliva produced. As many other bodily
functions are under cholinergic control, medications have
adverse effects such as constipation, urinary retention and
difficulties in hot weather due to reduced sweating. Blurred
vision, sedation, irritability and increased seizure frequency
are possible neurological effects [1]. There has never been a
study to investigate how different drug dosages should be
increased to achieve optimal balance between drug effect-
iveness and adverse effects, nor which drug achieves the
better balance [1]. In our survey [6], 98% of the 151 paedia-
tricians surveyed reported using medication for the treat-
ment of problematic drooling: 85% used hyoscine first line
and glycopyrronium second. Ninety-four percent of paedia-
tricians asked children and parents about the effectiveness
of medication; just over half also asked other professionals.
Only seven of the 151 paediatricians used a scale to moni-
tor effectiveness. Paediatricians generally considered that
hyoscine led to more adverse effects than glycopyrronium;hyoscine was also associated with more frequent dose re-
duction and withdrawal of medication [6].
Other interventions used to ameliorate drooling in-
clude [1]:
 Oro-motor exercises and postural management. There
is little evidence that they alone improve drooling
 Intra-oral devices. These are dangerous in children
with limited tongue movement, or epilepsy - each
commonly seen in children with neurodisability
 Surgical excision of or re-routing of salivary glands.
This can reduce drooling, but it is an invasive
procedure, and can be associated with negative effects
due to a lack of saliva, such as difficulty in chewing
 Botulinum toxin injection into the salivary glands
has shown benefits. However, injections (for which a
general anaesthetic is usually required) are needed
every six to twelve months. Botulinum is only
available through a few UK clinical services, and
therefore, few children can benefit
Methods and design
Aim
The aim of the study is to determine the clinical effect-
iveness and adverse effect profile of glycopyrronium and
hyoscine in children with problematic drooling.
Primary objective
To identify whether glycopyrronium or hyoscine is more
effective in treating drooling in children with non-
progressive disability.
Secondary objectives
To determine the most effective dosing schedule to
achieve optimum balance between clinical benefits and
adverse effects and to describe the reported satisfaction
with medication treatment of drooling for children and
carers.
Primary outcome measure
The primary outcome measure is the Drooling Impact
Scale (DIS) [7] score at four weeks, by which time all
children will be on the maximum tolerated dose of their
medication.
Secondary outcome measures
 Change in DIS score between baseline, 4, 12 and
52 weeks
 Change in Drooling Severity and Frequency Scale
(DSFS) score [8] at 4, 12 and 52 weeks
 Difference between the groups in the Treatment
Satisfaction Questionnaire for Medication (TSQM-
version II) score [9] at 4, 12 and 52 weeks
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maximum dose, compared between the two groups
 Relationship between dose and adverse effects,
investigated using survival analysis
 Children and young people’s perceptions of the
effectiveness and acceptability of the medications,
elicited in structured interviews
Study design
The study is a multi-centre (15 sites), randomised trial
of two commonly used medications, glycopyrronium
and hyoscine, in children with problematic drooling.
Medication type will be known to parent, child and clini-
cians but not the Trial Outcome Assessor (TOA). Ninety
children, who have never received medication for drool-
ing, will be recruited.
Subject population
The trial will recruit children with non-progressive neu-
rodisability who require treatment for drooling. This in-
cludes children with any neurodevelopmental disorder,
such as cerebral palsy or Down syndrome, where the
primary cause of disability is non-progressive (the motor
and functional disability of children may change as they
age but the primary cause of the neurodisability does
not worsen). Children with progressive disability will not
be included in the study as their oro-motor impairment
may worsen over time, making interpretation of re-
sponse to medication difficult.
Inclusion criteria
Treatment naive children, with non-progressive neurodi-
sability, who require glycopyrronium or hyoscine to re-
duce drooling
 No contra-indication to either medication
 Age ≥ 36 months to under 16 years at the start of
trial medication
 Weight ≥ 10 kg
Exclusion criteria
 Children who have received medical or surgical
interventions for drooling
 Children with medical conditions for which either
medication is contraindicated
 Children whose parents are considered unable to
follow the study protocol
 Parents without a mobile or home telephone
 Parents who cannot complete a telephone call in
English
 Children already in another clinical trial that
involves trial medication that could affect drooling,
or drooling management Pregnancy
 Previous withdrawal from this studyIdentification and recruitment of participants
Recruitment of participants is by the local paediatrician
during standard clinical care. The paediatrician explains
the study and gives the parent written information; when
appropriate, written information is also given to the
child.
We offer three recruitment approaches to suit the
family and local paediatrician:
1. If the parent has no doubts about their child taking
part in the trial, they can sign the consent form
straight away. The local paediatrician randomises
the patient to a treatment arm using the online
randomisation system. The family can then collect
the medication from the hospital pharmacy. It is
unusual to seek consent straight away but for the
reasons that follow, we received permission from the
Research Ethics Committee (REC) to allow this:
 The trial takes place in the context of routine
clinical practice and the medicines are already
being used
 It is more convenient for families to collect the
medication from the hospital straight away.
Otherwise the family, who might have travelled
considerable distances to attend, would have to
travel back to the hospital to pick up the
medication
 The medication does not start on the day of
consent. The Trial Research Paediatrician (TRP)
phones the family the next day to ensure that
the family has no doubts or any further
questions about trial participation.or
2. Families, whose paediatrician may be in a community
clinic without web access, can sign the consent form
and the family goes home without medication. The
TRP or local paediatrician then does the
randomisation as soon as possible, and then phones
the family who collect the medication from the
hospital, or it is sent to them by secure pharmacy
courier.or
3. The family may want to think further about whether
they want their child to join the trial. If subsequently
they want to participate, approach 1 or 2 above
would be adopted.Consent procedures
The local paediatrician takes written consent from par-
ents. Assent is sought from children deemed able to give
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paediatrician.
The original signed consent form is retained in the Inves-
tigator site file, with a copy in the clinical notes and a copy
provided to the participant. The participant consents to
their family doctor being informed of their participation in
the study. In addition, they are asked to consent to the per-
son who gives medication in school to be informed of their
child’s participation in the trial, and for that person to con-
tact the TRP if necessary.
For eligible families who do not want to take part in the
trial, we will record the reasons given for nonparticipation.
The study has ethical approval to collect the following data
from non-participants to enable investigation of representa-
tiveness of the study families: child’s neurodisability diagno-
sis, sex, year of birth, and parent’s postcode (to enable an
assessment of social bias).
Randomization and blinding
Stratification is by two criteria:
 Severity of salivation over the previous week using
the modified Mier classification [10]:
 Saliva usually only on lips or chin
 Saliva on lips, chin and clothes
 Clinical centre
Randomization is via a password-protected web-based
service provided by the Newcastle Clinical Trials Unit.
Patients are allocated to one of the two therapies in the
ratio 1:1 using random permuted blocks of variable
length. The sequence is revealed after data lock. Ran-
domisation occurs after recruitment, at least 24 hours
before start of medication.
Intervention
The medication regime is:
1. Glycopyrronium arm
Week 1: 40mcg/kg/per dose
Week 2: 60mcg/kg/per dose
Week 3: 80mcg/kg/per dose
Week 4: 100mcg/kg/per dose
All doses three times a day, adjusted according to
response up to maximum 2 mg per dose.
The medication is given by syringe orally or by a
child’s feeding tube.
2. Hyoscine arm
Week 1: ¼ patch
Week 2: ½ patch
Week 3: ¾ patch
Week 4: full patch
The patch is placed below the ear and is replaced
every three days, alternating sites to minimise therisk of a local skin reaction. The backing of the
patch is cut to expose the prescribed portion of the
patch; the patch itself is not cut because it is a
reservoir patch that would leak product. An
occlusive dressing is then applied over the patch as
per usual clinical practice.
In either arm, medication is increased weekly
through the trial from weeks 1 to 4; thereafter, or
when the maximum tolerated dose is achieved, the
participants will remain on that dose. Trial
medication then continues for 12 weeks.Stages for the family
Participants receive a study medication pack which
contains: study medication with labelling; parent in-
formation sheet to accompany medication; informa-
tion sheet regarding telephone calls; and occlusive
dressings (when in the hyoscine arm). Within a day
of randomisation the family is phoned by the TRP,
who confirms continued willingness to be in the trial
and addresses any queries. The family then receives
weekly phone calls from the TRP and the medication
dosage is adjusted up to four weeks. Weekly phone
calls continue to six weeks, then fortnightly to twelve
weeks with side effect information being actively
sought and noted at each call. At 12 weeks, the child
exits the trial and care is returned to the local
paediatrician at a pre-arranged appointment. Medica-
tion, packaging and any remaining medication is
returned to local pharmacies for destruction. All fam-
ilies will receive a final phone call nine months later
(one year after starting medication) to record their
medication type and dose at that date. These stages
are summarised in Table 1.
Within a day of randomisation the family is also
phoned by the TOA, who is blind to the treatment arm,
to gather baseline data. Each time the TOA contacts the
family she reminds them that she should not be in-
formed of the treatment arm the participant is in.Side effects and adverse events
Dose dependent, predictable side effects are not
regarded as adverse events. These side effects are
reviewed at the weekly telephone conversation with the
TRP for the first six weeks and fortnightly until week
twelve. Parents can contact the TRP to discuss side ef-
fects or concerns between 0900 and 1700 during the
week; out of usual daytime hours, the parent should
contact their family doctor or local child health service.
Any participant reporting clinically significant side ef-
fects will have their dose decreased to the previous
week’s dose, which will then be continued for the dur-
ation of the 12 week trial.
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Elective or scheduled treatment for pre-existing conditions
that did not worsen during the study or any pre-planned
hospitalisations not associated with clinical deterioration
are not regarded as adverse events. If serious adverse
events are reported over the telephone, the participant will
be advised to seek local medical attention. If serious ad-
verse events present to local services for management
(whether or not related to the investigational medication),
they will be brought to the attention of the Chief Investi-
gator (CI) immediately and he shall determine seriousness
and causality in conjunction with involved medical practi-
tioners. The CI and Trial Manager are responsible for
reporting all treatment-related serious adverse events to
the REC and Trial Sponsor within the relevant time
frames.Interviews with young people
The TRP will visit a subset of families whose children have
sufficient age, cognitive and communication ability to
report their opinion about their drooling and treatment in
a structured interview. When necessary, children will be
supported by their parents or local professionals to use
any usual communication aids. Interviews will take
place in home or at school. The aim of these interviews
is to set the primary and secondary outcomes of the
study in the context of a child’s experience. Some ex-
ample questions are shown in Table 2.
Children will be asked to indicate their response to
questions verbally or by pointing/eye pointing to visual
symbols printed above written words in the response
sets below.Concomitant medication and treatment
Other medication and treatment is prescribed or admin-
istered as required by local health providers in usual
clinical care; details are recorded in the case report form
(CRF).
Researcher skills
The TRP is a paediatric registrar, EW, with a specialist
interest in community paediatrics. She has six years’ ex-
perience in paediatric medicine, including one year in
community paediatrics and three months in paediatric
neurology. When absent for any reason, her role will be
covered by JP or AC, both consultant paediatricians.
The TOA has had training in the use of the outcome
tools, including pilot telephone calls with non-
participants.
Data collection, storage and record keeping
The local paediatrician provides the TRP and TOA with
the patient’s name, address, postcode and telephone
number via the secure National Health Service (NHS)
Email system or secure fax. He/she also provides data
about main neurodisability diagnosis and other relevant
clinical features. The online randomisation system gen-
erates a unique study number that identifies the patient;
this number is used by central trial staff when discussing
the patient with the local paediatrician. Assessments col-
lected by the TOA and drug dosage, side effects and ad-
verse event data collected by the TRP are entered on
paper, then transferred to a database, with a Good Clin-
ical Practice (GCP) [11] compliant electronic data cap-
ture system. In order for a link to be made with the
patient name and the study number, a log is kept in the
Table 2 Sample questions for the structured interview of
a subset of families and children
You are taking medicine for your drooling - it is the patch behind your
ear or the medicine you take
Do you think the medicine worked? yes/no/not sure




What is your drooling like now? very bad/bad/OK/
good/very good
Has the medicine helped you? yes/no/not sure
If yes, how has it helped you? Symbols for face not sore, dry chin, dry
clothes, friends, happy.
Have you felt unwell/poorly (word used by
family) whilst taking the medicine?
yes/no/not sure
If unwell:
Which part of you has felt unwell? Cartoon of a child, child points to
relevant body parts or interviewer points to each part of the body.
How unwell have you felt? OK/bad/very bad
Did you feel unwell like that before you took
the medicine?
yes/no/not sure
Did you want to stop taking the medicine? yes/no/not sure
Are you still feeling unwell? yes/no/not sure
Did you tell your mum/dad about this? yes/no/not sure
If no: ‘I think I should tell them and we can talk about how to help you
get better’
If a friend needed help for their drooling,
should they take the medicine you have tried?
yes/no/not sure
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patient identifiable information is kept in a locked cabinet,
with access limited to authorised members of the research
team. All study data are retained and handled in accord-
ance with GCP [11] and local policy and in accordance
with the Data Protection Act 1998. Documentation of pre-
scribing, dispensing and return of study medication is
maintained for study records. The final trial dataset will
be initially available only to the study team; after the re-
sults of the trial have been reported, anonymous trial data
will be made publicly available.Sample size calculation
The primary outcome measure is the DIS (range 0 to
100), which has a standard deviation of 13 [7]. The study
is powered to detect a clinically significant difference of
10.0 in the mean score between groups, representing
what parents viewed as the difference between ‘very
good to excellent’ and ‘good’ in a global rating. To detect
this mean difference of 10.0 with 90% power, assuming a
type 1 error rate of 5%, data from two groups of 36 are
required. Allowing for 20% loss to follow up or attrition,
recruitment and randomisation of 90 children is needed.A final sample size of 72 gives 90% power to detect an
effect size of 0.77 in the secondary outcome measures.
For the TSQM, this corresponds to mean differences of
18.2, 17.6, 13.2 and 16.5 in the effectiveness, side effects,
convenience and overall satisfaction subscales respectively.
Statistical analysis
Data will be analysed by the trial statistician using SPSS
software (Armonk, NY, USA).
For the primary outcome analysis, the DIS score at
four weeks will be compared between the two groups
using an independent sample t-test.
The secondary outcomes will be analysed as follows:
 Change in DIS score between baseline, 4 weeks,
12 weeks and 52 weeks; we will use repeated
measures analysis of variance to look at changes in
the DIS over time comparing the two groups
 Change in DSFS score; we will use repeated
measures analysis of variance to look at changes in
the DSFS over time comparing the two groups
 Difference between the groups in the TSQM score;
we will use repeated measures analysis of variance
to look at changes in the TSQM over time
comparing the two groups
 The final medication doses, as a percentage of child’s
maximum dose, will be compared between the two
groups with the exact Mann–Whitney test
 The relationship between dose and adverse effects
will be investigated using survival analysis. The
dependent variable will be the dose corresponding
to a side effect that was deemed to be ‘not tolerable’.
Observations are censored if (i) maximum dose is
reached with no side effects or (ii) a decision is
made not to increase the dose for any other reason.
The two groups will then be compared using a Cox
proportional hazards model. Results will be given
with a 95% confidence interval for the hazard ratio.
The impact of missing data will be assessed using a
sensitivity analysis. Any data imputation will depend
upon the level of missing data and its pattern. There will
be no interim analysis.
Data from the structured interviews will by synthesised
by the TRP in collaboration with the trial statistician.
Summary statistics will be mainly descriptive; where ap-
propriate interval estimates of parameters of interest will
be generated (for example for the proportion of respon-
dents reporting positive responses to a particular issue).
Withdrawal of participants
Participants have the right to withdraw from the study
at any time for any reason, and without giving a reason.
The Investigator also has the right to withdraw patients
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verse events, serious adverse events, suspected unex-
pected serious adverse reactions, protocol violations, or
administrative reasons. Where families withdraw without
starting medication or within the first 48 hours, they will
be replaced.
Should a patient or parent decide to withdraw from
the study, they will notify the local paediatrician or the
TRP. All efforts will be made to report the reason for
withdrawal as thoroughly as possible. The TRP will send
parents who decide to withdraw a Withdrawal Letter.
They will be asked if they agree to data collected prior
to their child’s withdrawal from the study being used for
the purposes of the trial, and whether they agree to one
phone call about what happened with the management
of their child’s drooling (at one year after starting the
study). If the participant and family wish to withdraw
completely then none of their data will be analysed.
Discontinuation rules
The trial may be prematurely discontinued on the basis
of new safety information, or for other reasons given by
the Data Monitoring and Ethics Committee (DMEC),
Trial Steering Committee (TSC), Sponsor, regulatory au-
thority or ethics committee (see below). For individual
participants, the study drug will be discontinued if there
are adverse effects that warrant this, or the participant
requests it.
Management of the trial, quality control and assurance
The trial is managed through Newcastle Clinical Trials
Unit (CTU) and the research team’s Trial Management
Group (TMG).
The Principal Investigators at the recruiting sites are
responsible for the day-to-day study conduct at their
sites. Newcastle CTU provides day-to-day support for
the sites and provides training through Investigator
meetings, site initiation phone calls and routine moni-
toring. Quality control is maintained through adherence
to the study protocol, study specific working instruc-
tions, the principles of GCP [11], research governance
and clinical trial regulations.
An independent DMEC consisting of independent
chair, two physicians not connected to the trial, and one
statistician, will provide independent review. Its purpose
is to monitor efficacy and safety endpoints. The DMEC
will have access to unblinded study data. The committee
will have discussions (not necessarily face to face) at
least three times: around the start of the trial, six
months into recruitment and at the end of the study. At
the first meeting, the DMEC will discuss and advise on
the inclusion of an interim analysis at five months, and
possible adoption of a formal stopping rule for efficacy
or safety.A TSC with an independent chair will provide overall
supervision of the trial. The TSC will meet every six
months during the trial. Its role is to monitor progress
and supervise the trial to ensure it is conducted to high
standards in accordance with the protocol, the principles
of GCP, relevant regulations and guidelines with regard
to participant safety.
The Trial Manager from the CTU will ensure that the
study is conducted in accordance with GCP. The Trial
Manager’s main areas of focus will include consent, ser-
ious adverse events, essential documents in study files
and drug accountability. Monitoring of study processes
will have two components:
1. Central monitoring of each recruiting site will
involve:
 Checking inclusion/exclusion criteria and consent
processes
 Version verification of consent form for 100% of
patients
 Confirmation via checklist of all essential
documentation being present in the site file;
including regulatory approvals and amendments
 Checking eligibility data for 10% of participants
entered in the study
 Checking drug accountability and management
2. Central monitoring of data collected by the TRP and
TOA at Newcastle will start soon after the first
participant has been recruited, and will then be
undertaken again six months into recruitment.
Monitoring will involve verification of 10% of
reported serious adverse events against source data,
and review of primary endpoint data.
Plans to communicate trial results to participants and the
public
The results of the trial will be sent to all participants
and will be submitted to a peer reviewed journal for
publication. The results will be used to develop evidence
based guidance to inform the medical treatment of
drooling.
Protocol publication
This protocol has been written according to and in ad-
herence with recommendations from the SPIRIT check-
list: recommended items to address in a clinical trial
protocol and related documents [12].
Ethics committee and regulatory approval
The study will be conducted in accordance with ethical
principles as listed in the Declaration of Helsinki [13].
Ethics approval was granted by Newcastle and NorthTyne-
side1 REC on 10 May 2013, number 13/NE/0078. A first
substantial amendment was approved on 23 July 2013. A
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September 2013 before commencing the trial recruitment
on 24 October 2013. (Trial Protocol version 2.0, 19/8/13).
If further protocol amendments are needed, approval
will be sought from the Sponsor and then submitted to
the REC.
Discussion
This study will determine whether there is a difference
in the effectiveness of the two trial medications, and
which doses are associated with least side effects. This
information will be used to develop evidence-based
guidance to help children, parents and doctors: firstly to
decide which medication to prescribe to reduce prob-
lematic drooling and at what dose; secondly to show
how adverse effects can be monitored, and when dosage
should be reduced or medication stopped.
The study will benefit children with neurodisability
who drool, and their families. By identifying how best to
choose medication, decide on dosage and monitor effect
and side effects, this applied research relates to the day
to day practice of health service staff - specifically, paedi-
atricians and speech and language therapists. Children’s
drooling will be better controlled with the accompanying
physical and psychosocial benefits for child and family.
Trial status
The trial is in progress at a number of sites and started
to recruit in October 2013.
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